AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~β carboline derived guanidine alkaloid, tiruchenduramine of the~~ A compound of Formula 1



1

and tautomers, stereoisomers, analogs, anhydrides, prodrugs, and pharmaceutically acceptable salts and solvates ~~isolated from an ascidian *Synoicum macroglossum* and its derivatives~~ thereof.

2. (Currently amended) A compound ~~as claimed in claim 1~~ having the following formula ~~selected from the following~~:



wherein n is 2 to 6; Q is NH or O; and R_1 is H or piperazine,

and tautomers, stereoisomers, analogs, anhydrides, prodrugs, and pharmaceutically acceptable salts and solvates thereof.

	
~~1. R_1=R_2=R_3=H, n=2~~	~~6. R_1=R_2=R_2=H, n=2~~

~~2. R_1=R_2=R_3=H, n=3~~ ~~3. R_1=R_2=R_3=H, n=4~~ ~~4. R_1=R_2=R_3=H, n=5~~ ~~5. R_1=R_2=R_3=H, n=6~~	~~7. R_1=R_2=R_3=H, n=3~~ ~~8. R_1=R_2=R_3=H, n=4~~ ~~9. R_1=R_2=R_3=H, n=5~~ ~~10. R_1=R_2=R_3=H, n=6~~
	
~~11. R_1= Piperzine, R_2=R_3=H, n=2~~ ~~12. R_1= Piperzine, R_2=R_3=H, n=3~~ ~~13. R_1= Piperzine, R_2=R_3=H, n=4~~ ~~14. R_1= Piperzine, R_2=R_3=H, n=5~~ ~~15. R_1= Piperzine, R_2=R_3=H, n=6~~	~~16. R_1= Piperzine, R_2=R_3=H, n=2~~ ~~17. R_1= Piperzine, R_2=R_3=H, n=3~~ ~~18. R_1= Piperzine, R_2=R_3=H, n=4~~ ~~19. R_1= Piperzine, R_2=R_3=H, n=5~~ ~~20. R_1= Piperzine, R_2=R_3=H, n=6~~

3. (Currently amended) A process for the preparation of a compound according to claim 1 ~~β carboline derived guanidine alkaloid tiruchenduramine of Formula 1~~



~~1~~

which comprises subjecting an ascidian to solvent extraction.

4. (Currently amended) A process as claimed in claim 3 wherein said ascidian is *Synoicum macroglossum*.

5. (Previously presented) A process as claimed in claim 3 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

6. (Previously presented) A process as claimed in claim 5 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

7. (Previously presented) A process as claimed in claim 6 wherein said dichloromethane and methanol are used in a ratio of 1:1.

8. (Previously presented) A process as claimed in claim 7 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

9. (Previously presented) A process as claimed in claim 8 wherein said water extract is lyophilized and the residue is triturated with methanol.

10. (Previously presented) A process as claimed in claim 5 wherein said purification comprises a Sephadex LH-20 column chromatography.

11. (Currently amended) A pharmaceutical composition comprising as an active ingredient a compound according to claim 1 ~~of Formula 1~~, and



~~1~~

a pharmaceutically acceptable carrier, vehicle or excipient.

12. (Currently amended) A pharmaceutical composition comprising as an active ingredient a compound according to ~~as claimed in~~ claim 2 and a pharmaceutically acceptable carrier, vehicle or excipient.

13. (Currently amended) A composition as claimed in claim 11 ~~wherein said composition is used for the treatment of diabetic disorders and~~ wherein said active ingredient is present in an amount of about 78.8 μg.

14. (Previously presented) A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

15. (Currently amended) A pharmaceutical composition comprising a first therapeutic agent consisting of a compound according to claim 2 ~~β-carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20~~ and a second therapeutic agent different from said first therapeutic agent.

16. (Previously presented) A composition as claimed in claim 15 wherein said second therapeutic agent is selected from alkylating agents, antimetabolites, vinca alkaloids, antibiotics, cytokines, growth factors and non-steroidal anti-inflammatory drugs.

17. (Currently amended) A method of treating diabetic disorders in a mammal in need thereof wherein the method comprises administration of a compound according to claim 2 ~~β-carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20~~.

18. (Currently amended) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a compound according to claim 2 ~~β carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20~~.

19. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 11.

20. (Previously presented) A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

21. (Currently amended) A composition as claimed in claim 12 ~~wherein said composition is used for the treatment of diabetic disorders and~~ wherein said active ingredient is present in an amount of about 78.8 μg.

22. (Previously presented) A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

23. (Previously presented) A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

24. (Previously presented) A process as claimed in claim 4 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

25. (Previously presented) A process as claimed in claim 24 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

26. (Previously presented) A process as claimed in claim 25 wherein said dichloromethane and methanol are used in a ratio of 1:1.

27. (Previously presented) A process as claimed in claim 26 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

28. (Previously presented) A process as claimed in claim 27 wherein said water extract is lyophilized and the residue is triturated with methanol.

29. (Previously presented) A process as claimed in claim 6 wherein said purification comprises a Sephadex LH-20 column chromatography.

30. (Previously presented) A process as claimed in claim 7 wherein said purification comprises a Sephadex LH-20 column chromatography.

31. (Previously presented) A process as claimed in claim 8 wherein said purification comprises a Sephadex LH-20 column chromatography.

32. (Previously presented) A process as claimed in claim 9 wherein said purification comprises a Sephadex LH-20 column chromatography.

33. (Previously presented) A process as claimed in claim 24 wherein said purification comprises a Sephadex LH-20 column chromatography.

34. (Previously presented) A process as claimed in claim 25 wherein said purification comprises a Sephadex LH-20 column chromatography.

35. (Previously presented) A process as claimed in claim 26 wherein said purification comprises a Sephadex LH-20 column chromatography.

36. (Previously presented) A process as claimed in claim 27 wherein said purification comprises a Sephadex LH-20 column chromatography.

37. (Previously presented) A process as claimed in claim 28 wherein said purification comprises a Sephadex LH-20 column chromatography.

38. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 12.

39. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 13.

40. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 14.

41. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 15.

42. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 16.

43. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 20.

44. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 21.

45. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 22.

46. (Previously presented) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 23.

47. (Currently amended) A composition ~~of~~ as claimed in claim 16, wherein the non-steroidal anti-inflammatory is aspirin.